ZEVRA THERAPEUTICS INC. - COMMON STOCK

7.9200

12-March-25 16:45:02

15 minutes delayed

Stocks

-0.1500

-1.86%

Today's range

7.3200 - 8.2999

ISIN

N/A

Source

NASDAQ

Zevra Therapeutics to Participate at Upcoming Investor Conferences

29 Aug 2024 07:30:00 By Nasdaq GlobeNewswire
Zevra Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights

13 Aug 2024 16:05:00 By Nasdaq GlobeNewswire
Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock

09 Aug 2024 00:00:03 By Nasdaq GlobeNewswire
Zevra Therapeutics Announces Proposed Public Offering of Common Stock

08 Aug 2024 16:01:00 By Nasdaq GlobeNewswire
Zevra Therapeutics to Present at Canaccord Genuity’s 44th Annual Growth Conference

07 Aug 2024 09:34:47 By Nasdaq GlobeNewswire
FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C

02 Aug 2024 17:50:37 By Nasdaq GlobeNewswire
Zevra Therapeutics to Report Second Quarter 2024 Financial Results

30 Jul 2024 08:38:30 By Nasdaq GlobeNewswire
Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

09 Jul 2024 09:00:00 By Nasdaq GlobeNewswire
Zevra Therapeutics Expands Executive Leadership Team

25 Jun 2024 07:30:00 By Nasdaq GlobeNewswire
Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders

18 Jun 2024 07:30:00 By Nasdaq GlobeNewswire
Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting

03 Jun 2024 11:00:00 By Nasdaq GlobeNewswire
Zevra Therapeutics to Participate at Upcoming Investor Events

09 May 2024 07:30:00 By Nasdaq GlobeNewswire
Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates

08 May 2024 07:00:01 By Nasdaq GlobeNewswire
Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024

01 May 2024 07:30:00 By Nasdaq GlobeNewswire
Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024

29 Apr 2024 07:30:00 By Nasdaq GlobeNewswire
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting

15 Apr 2024 17:01:44 By Nasdaq GlobeNewswire
Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility

10 Apr 2024 07:30:00 By Nasdaq GlobeNewswire
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

28 Mar 2024 16:32:04 By Nasdaq GlobeNewswire
Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia

26 Mar 2024 16:30:00 By Nasdaq GlobeNewswire
Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

25 Mar 2024 16:30:00 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.